Cannabis for medical use

Leoš Landa

Department of Pharmacology

Cannabinoids

Group of 21 carbon terpenophenolic compounds uniquely produced by hemp plants

NEED FOR A CHANGE OF THE ORIGINAL MEANING

Development of synthetic cannabinoids

Discovery of endogenous cannabinoids (endocannabinoids)

Cannabinoids

Phytocannabinoids
= substances contained specifically in hemp

Endocannabinoids
= natural cannabinoids in the body of animals and human beings

Synthetic cannabinoids
= artificially produced

Phytocannabinoids
subclasses according to Elsohly et al. (2005):

1) cannabigerol type

2) cannabichromene type

3) cannabidiol type (CBD)

4) Δ9- trans-tetrahydrocannabinol type (THC)

5) Δ8-trans-tetrahydrocannabinol type

6) cannabicyclol type

7) cannabielsoin type

8) cannabinol type

9) cannabinodiol type

10) cannabitriol type

Department of Pharmacology

11) miscellaneous types

MUNI
MED

https://cs.wikipedia.org/wiki/Soubor:HanDev.jpg

Lumír Hanuš

William Devane

Department of Pharmacology

Endocannabinoids

anandamide (N-arachidonoyl-ethanolamine, AEA) (Devane et al. 1992)

name based on the Sanskrit word 'ananda' (internal bliss)

2-arachidonoyl-glycerol (2-AG) (Mechoulam et al. 1995)

N-arachidonoyl-dopamine (NADA) (Bisogno t al. 2000)

noladin ether (2-arachidonyl-glyceryl ether, 2-AGE) (Hanus et al. 2001)

virhodamine (O-arachidonoyl-ethanolamine) (Porter et al. 2002)

Synthetic cannabinoids

Main purpose:
study of distribution and pharmacological
properties of cannabinoid receptors

HU-210 (CB$_1$ a CB$_2$ receptor agonist)

methanandamide (CB$_1$ receptor agonist)

CP 55,940 (CB$_1$ a CB$_2$ receptor agonist)

WIN 55,212-2 (CB$_1$ receptor agonist)

JWH 015 (CB$_2$ receptor agonist)

AM 251 (CB$_1$ receptor antagonist)

Cannabinoids - mechanism of action (endocannabinoid system)

Cannabinoid receptors

Endocannabinoids

Enzymes
(biosyntesis/degradation)

Cannabinoid receptors CB_1 and CB_2

CB_1 receptors - primarily in the CNS
regions of the brain responsible for **pain modulation**: certain parts of the spinal cord, periaqueductal grey (Grotenhermen 2006)
movement: basal ganglia, cerebellum
memory and learning: hippocampus, cerebral cortex
emotions: amygdala
sensory perception: thalamus (Velasco et al. 2012)

RESPONSIBLE FOR PSYCHOACTIVE EFFECTS

CB_2 receptors - particularly in the periphery
on immune cells, especially B-cells and natural killer cells (Pertwee 1997), also expressed in tonsils or spleen (Galiegue et al. 1995)

MUNI
MED

Other known cannabinoid receptors:

TRPV1 receptors

transient receptor potential cation channels subfamily V member 1

- also known as the "capsaicin receptor" and "vanilloid receptor (Ross 2003)

GPR18, GPR55, GPR119

(also called putative or non-classical cannabinoid receptors)

- structural similarity to CB_1 and CB_2
(Alexander et al. 2013; Zubrzycki et al. 2014)

Synthesizing enzymes:

phospholipases

Degrading enzymes:

FAAH

(fatty acid amide hydrolase; post-synaptically)

MAGL

(monoacylglycerol lipase; pre-synaptically)

(Pertwee 2005; Muccioli 2010; Battista et al. 2012)

Endocannabinoids
- mechanism of action

NTs bind to their receptors →
activated postsynaptic neurons synthesize
endocannabinoid precursors

→ subsequent release of endocannabinoids

(This is generally induced by an increase in the cytosolic
concentration of free Ca^{2+})

Endocannabinoids - mechanism of action (THC)

Endocannabinoids act as retrograde synaptic messengers → bind to presynaptic CB_1 cannabinoid receptors

→ inhibition of NTs release: glutamate and GABA (Guzman, 2003).

http://30c1be84fhhqj3xa1lmshckme-wpengine.netdna-ssl.com/wp-content/uploads/2015/09/endocannabinoid-natur.jpg

MUNI
MED

Physiological functions of ECS are very complex:

motor coordination

memory

appetite

modulation of pain

neuroprotective effects

maintaining of homeostasis, etc. (Pacher et al., 2006).

Effect of THC on dopamine release
→ dependence potential

THC stimulates neurons in dopamine reward system to release (indirectly)

GABA normally suppresses amount of dopamine released in nucleus accumbens.

GABA is blocked by THC → increase in dopamine release

Effect of THC on dopamine release → dependence potential

thebrain.mcgill.ca

Main medical purposes of use

chronic persistent pain – especially in association with cancer,

neuropathic pain, pain associated with glaucoma,

pain associated with degenerative disease of the musculoskeletal system,

spasticity and pain in multiple sclerosis,

tremor caused by Parkinson's disease,

nausea and vomiting particularly following cancer treatment,

stimulation of appetite in cancer and HIV patients,

Tourette syndrome

superficial treatment of dermatosis and mucosal lesions